胃と腸43巻5号

2008年04月発行

今月の主題 linitis plastica型胃癌―病態と診断・治療の最前線 主題

linitis plastica型胃癌の治療戦略（staging診断も含めて）―内科的治療

著者： 今澤雅子¹ 安井博史¹ 朴成和¹

所属機関： ¹静岡県立静岡がんセンター消化器内科

ページ範囲：P.825 - P.831

要旨　linitis plastica（LP）型胃癌は早期発見が困難であり，発育や進展が速いため外科的切除術後の予後は不良と言われている．また，腹膜転移を来しやすく，腸閉塞，水腎症，腹水，閉塞性黄疸のために全身状態が不良となり，臨床試験の対象から外れることが多いため，標準治療が定まっていないのが現状である．そのため，LP型胃癌治療は，患者個々の全身状態や病態に応じた治療戦略を構築することが重要である．

参考文献

1)磨伊正義，村俊成，奥村義治．「スキルス」胃癌の初期病変とは―早期発見へのアプローチ．外科治療86:1056-1064, 2002

2)古河洋，今村博司，龍田眞行．「スキルス」胃癌．外科治療86:1051-1055, 2002

3)岡島一雄．胃癌患者の予後因子―多変量解析による検討．日本消化器外科学会雑誌30:700-711, 1997

4) Japanese Gastric Cancer Association Registration Committee;Maruyama K, Kaminishi M, Hayashi K, et al. Gastric cancer treated in 1991 in Japan:data analysis of nationwide registry. Gastric Cancer 9:51-66, 2006

5) Yoshikawa T, Tsuburaya A, Kobayashi O, et al. Should scirrhous gastric carcinoma be treated surgically?Clinical experiences with 233 cases and a retrospective analysis of prognosticators. Hepatogastroenterology 48:1509-1512, 2001

6) Yamao T, Shimada Y, Shirao K, et al. Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites:a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial. Jpn J Clin Oncol 34:316-322, 2004

7) Tahara M, Ohtsu A, Boku N, et al. Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination:a retrospective study. Gastric Cancer 4:212-218, 2001

8)田口鐵男，坂田優，金丸龍之介，他．進行・再発胃癌に対するRP56976(Docetaxel)後期第II相臨床試験:多施設共同研究(Aグループ)．癌と化学療法25:1915-1924, 1998

9)磨伊正義，坂田優，金丸龍之介，他．進行・再発胃癌に対するRP56976(Docetaxel)後期第II相臨床試験:多施設共同研究(Bグループ)．癌と化学療法26:487-496, 1999

10) Mitachi Y, Sakata Y, Ohtsu A, et al. Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer:a multicenter phase I/II study. Gastric Cancer 5:160-167, 2002

11) Yoshida K, Ninomiya M, Takakura N, et al. Phase II study of Docetaxeland S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12:3402-3407, 2006

12) Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group. J Clin Oncol 24:4991-4997, 2006

13) Yamada Y, Shirao K, Ohtsu A, et al. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 12:1133-1137, 2001

14) Yamaguchi K, Tada M, Horikoshi N, et al. Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer 5:90-95, 2002

15) Yoshida M, Boku N, Ohtsu A, et al. Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer:efficacy and feasibility in clinical practice. Gastric Cancer 4:144-149, 2001

16) Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma(FOLCETUX study). Ann Oncol 18:3510-3517, 2007

17) Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24:5201-5206, 2006

18) Aoyagi K, Kouhuji K, Yano S, et al. VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer 8:155-163, 2005